DDInter1600 DDInter1820
Riociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for the treatment of patients with inoperable CTEPH (chronic thromboembolic pulmonary hypertension), or persistent/recurrent PH (pulmonary hypertension) after pulmonary endarterectomy in WHO FC II or III. Riociguat is marketed under the brand Adempas® by Bayer HealthCare Pharmaceuticals. Treatment with riociguat costs USD $7,500 for 30 days of treatment.
Renal cell carcinoma (RCC) is responsible for 3% of cancer cases and is one of the 10 most common cancers in adults. The average age of diagnosis is between age 65 to 74. Tivozanib, also known as FOTIVDA, is a kinase inhibitor developed to treat adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) after prior failed systemic therapies. It was approved on March 10, 2021 by the FDA. Marketed by Aveo Oncology, tivozanib is a promising therapy for individuals with RCC who have not been treated successfully with other therapies.
Riociguat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rabeprazole
Riociguat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apalutamide
Riociguat {u} may lead to a major life threatening interaction when taken with {v} Dyphylline
Riociguat {u} may lead to a major life threatening interaction when taken with {v} Cobicistat
Riociguat may cause a moderate interaction that could exacerbate diseases when taken with Rabeprazole
Riociguat may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Riociguat may lead to a major life threatening interaction when taken with Dyphylline
Riociguat may lead to a major life threatening interaction when taken with Cobicistat